Johnson & Johnson vs. PTC Therapeutics, Inc.
Johnson & Johnson (JNJ) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| JNJ | PTCT | |
|---|---|---|
| Market Cap | $627.42 billion | $5.98 billion |
| Revenue (TTM) | $97.93 billion | $1.01 billion |
| Net Income (TTM) | $21.04 billion | $-38,382,000 |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | PTCT | |
|---|---|---|
| P/E Ratio | 30.20 | — |
| Price / Book | 7.38 | -36.19 |
| Price / Sales | 6.41 | 5.93 |
PTCT leads on 2 of 2 valuation factors.
Profitability
| JNJ | PTCT | |
|---|---|---|
| Net Margin | 21.48% | -3.80% |
| Return on Equity | 24.76% | 23.21% |
JNJ leads on 2 of 2 profitability factors.
Dividend
| JNJ | PTCT | |
|---|---|---|
| Dividend Yield | 2.06% | — |
| Payout Ratio | 62.18 | — |
JNJ and PTCT split the dividend factors evenly.
Risk & Sentiment
| JNJ | PTCT | |
|---|---|---|
| Short Interest | 0.67% | 7.88% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, PTCT overview, PTCT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.